Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Neoplasm Metastasis 5 Triple Negative Breast Neoplasms 3 Brain Neoplasms 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 HER2-positive Breast Cancer 2 Urinary Bladder Neoplasms 1 Thrombocytosis 1 Solid Tumor 1 Recurrence 1 Rare Tumour 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Meningioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Fulvestrant 6 olaparib 4 Letrozole 4 trastuzumab deruxtecan 3 Aromatase Inhibitors 3 Anastrozole 3 sacituzumab govitecan 2 pyrotinib 2 eribulin 2 dalpiciclib 2 Paclitaxel 2 Goserelin 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Capecitabine 2 toripalimab 1 talazoparib 1 sonidegib 1 ribociclib 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 elacestrant 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 balixafortide 1 apatinib 1 abemaciclib 1 Vorinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × neratinib × Clear all

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡